Merck: Release of the results of two Phase III trials studying the oral PCSK9 inhibitor Enlicitide Decanoate.

On November 20th, Merck recently announced the trial results of the phase III CORALreef Lipids and phase III CORALreef HeFH for the first time at the American Heart Association Scientific Sessions.